Solventum announced FDA clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.® Therapy, merging two advanced wound care technologies. This integration aims to streamline treatment and improve patient outcomes by supporting active wound healing through structural tissue repair and optimized wound environment. Restrata Matrix provides a synthetic scaffold that resists degradation and promotes tissue growth, while V.A.C. Therapy uses negative pressure to enhance healing and reduce infection risk. The combined therapy may reduce dressing changes and improve care efficiency, especially in complex wounds, marking a significant advancement in wound care management.
Solventum's FDA clearance for combined Restrata™ Matrix and V.A.C.® Therapy provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 150 priced US health-sector stocks, 87 rose and 62 fell. Notable movers include NVAX at USD 11.19 with a -12.71% change and a typical hold time of 59 days, MESO at USD 11.96 down -9.98% with a 16-day hold, and BNGO at USD 1.25 down -8.76% with a 51-day hold.
The Canadian Investment Regulatory Organization (CIRO) has temporarily halted trading of all shares of Bighorn Metals Corp. (symbol HRNY) as of 1:10 PM ET on October 19, 2026. The halt is pending further information from the company and aims to maint...
The HCA Healthcare Foundation awarded $25,000 to Waypoint (formerly Virginia Home for Boys and Girls) to expand its network of adults trained to support youth mental wellness across Virginia. This funding supports Waypoint's Therapeutic Resources tea...
Angle Advisors has appointed Chris Gessner as a Managing Director, bringing over 20 years of experience in corporate finance, including lending, private equity, and M&A advisory. Gessner's background spans various transaction types and industries suc...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
